Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations

Jazz Pharmaceuticals (JAZZ) reported fourth-quarter 2024 adjusted earnings of $6.60 per share, which beat the Zacks Consensus Estimate of$5.79. Earnings rose 31% year over year.Total revenues rose 8% year over year to $1.09 billion. Sales of Xywav and Epidiolex drove this upside. The reported figure beat the Zacks Consensus Estimate of$1.06 billion.See the Zacks Earnings Calendar to stay ahead of market-making news.Shares of Jazz rose more than 2% in pre-market today, likely due to the better-than-expecte ...